News
A new study published in Current Pharmaceutical Analysis reveals that cardiolipin dysregulation may be a key factor in bortezomib-induced peripheral neuropathy (BIPN). Using lipidomics and ...
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...
Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...
Detailed price information for Netramark Hldgs Inc (AINMF) from The Globe and Mail including charting and trades.
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming ...
Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...
There's a treatment helping chronic pain patients by disrupting pain signals in the body from getting to the brain.
Nervous system involvement was common among a cohort of patients with AAV, with these individuals showing less severe renal impairment.
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ...
The approval is supported by a study involving 453 adults with advanced platinum-resistant cancers of the ovary, fallopian ...
India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results